1. Home
  2. MDGL vs RDN Comparison

MDGL vs RDN Comparison

Compare MDGL & RDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • RDN
  • Stock Information
  • Founded
  • MDGL 2011
  • RDN 1977
  • Country
  • MDGL United States
  • RDN United States
  • Employees
  • MDGL N/A
  • RDN N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • RDN Property-Casualty Insurers
  • Sector
  • MDGL Health Care
  • RDN Finance
  • Exchange
  • MDGL Nasdaq
  • RDN Nasdaq
  • Market Cap
  • MDGL 6.4B
  • RDN 5.3B
  • IPO Year
  • MDGL N/A
  • RDN 1992
  • Fundamental
  • Price
  • MDGL $340.14
  • RDN $33.34
  • Analyst Decision
  • MDGL Buy
  • RDN Buy
  • Analyst Count
  • MDGL 14
  • RDN 5
  • Target Price
  • MDGL $351.67
  • RDN $36.30
  • AVG Volume (30 Days)
  • MDGL 392.5K
  • RDN 1.3M
  • Earning Date
  • MDGL 02-26-2025
  • RDN 02-05-2025
  • Dividend Yield
  • MDGL N/A
  • RDN 2.94%
  • EPS Growth
  • MDGL N/A
  • RDN N/A
  • EPS
  • MDGL N/A
  • RDN 3.86
  • Revenue
  • MDGL $76,813,000.00
  • RDN $1,303,066,000.00
  • Revenue This Year
  • MDGL N/A
  • RDN N/A
  • Revenue Next Year
  • MDGL $195.95
  • RDN $3.15
  • P/E Ratio
  • MDGL N/A
  • RDN $8.61
  • Revenue Growth
  • MDGL N/A
  • RDN 6.23
  • 52 Week Low
  • MDGL $168.25
  • RDN $26.11
  • 52 Week High
  • MDGL $368.29
  • RDN $37.86
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 61.81
  • RDN 57.33
  • Support Level
  • MDGL $266.44
  • RDN $32.94
  • Resistance Level
  • MDGL $343.97
  • RDN $33.48
  • Average True Range (ATR)
  • MDGL 20.88
  • RDN 0.59
  • MACD
  • MDGL 2.00
  • RDN 0.29
  • Stochastic Oscillator
  • MDGL 92.59
  • RDN 95.42

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

About RDN Radian Group Inc.

Radian Group Inc provides mortgage insurance and services to the real estate and mortgage finance industries. Radian's mortgage insurance provides coverage to lending institutions throughout the United States. Its services include analytics and consulting for buyers and sellers of, and investors in, mortgage- and real estate-related loans and securities and other asset-backed securities. Insurance premiums account for more than three fourths of the company's revenue. Services revenue and investment income are the other principal sources of revenue. It operates in two segments: Mortgage and homegenius. The Mortgage segment earns the majority of revenue.

Share on Social Networks: